Most Recent Episode
ASCO 2024: What the ESOPEC, RENAISSANCE, and ARMANI Trials Mean for the Future of Esophageal Cancer Treatment Drs Samuel Klempner and Yelena Janjigian break down major takeaways from the clinical trial data presented at ASCO 2024. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999887. The topics...
Time: 19:37
Drs Samuel Klempner and Yelena Janjigian break down major takeaways from the clinical trial data presented at ASCO 2024.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999887. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Esophageal Cancer https://emedicine.medscape.com/article/277930-overview
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial https://pubmed.ncbi.nlm.nih.gov/33891478/
Prospective Randomized Multicenter Phase III Trial Comparing Perioperative Chemotherapy (FLOT Protocol) to Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus (ESOPEC Trial). https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA1
The RENAISSANCE (AIO-FLOT5) Trial: Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction – A Phase III Trial of the German AIO/CAO-V/CAOGI https://pubmed.ncbi.nlm.nih.gov/29282088/
MATTERHORN: Phase III Study of Durvalumab Plus FLOT Chemotherapy in Resectable Gastric/Gastroesophageal Junction Cancer https://pubmed.ncbi.nlm.nih.gov/35535555/
First-Line Nivolumab Plus Chemotherapy vs Chemotherapy Alone for Advanced Gastric, Gastro-oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/34102137/
Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma: Interim Analyses From the Phase 3 KEYNOTE-811 Randomised Placebo-Controlled Trial https://pubmed.ncbi.nlm.nih.gov/37871604/
Assessment of Ramucirumab Plus Paclitaxel as Switch Maintenance Versus Continuation of First-Line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers: The ARMANI Phase III Trial https://pubmed.ncbi.nlm.nih.gov/30922323/
GUID: facbdc43-7646-46f4-8af6-d157b599e5ce
Release Date: 29/10/2024, 18:59:57
